CRISPR tech selectively shreds cancer cells, including "undruggable" cancers
An Internet at the Innovative Genomics Institute (business model: 'Uber for Doudna’s lecture fees') has invented a new way to atomize cells carrying a mutation found in 47% of all cancer cases, using a molecular shredder that works like a one-way ticket to the cytoplasm. Hackernews, literally all of whom hold a PhD in either tumor biology or the art of screaming into the void, immediately descend to point out that this is both the second coming of gene therapy and a complete waste of funding, while also engaging in a heated round of “my treatment is more FDA-approved than your treatment” that would make a patent lawyer blush. Of course, the actual delivery problem—getting this thing into a living human without the liver dissolving in a puddle of immune rage—is hand-waved away with a reference to lipid nanoparticles that have already been tested on exactly six people, three of whom died of fungal infections. The stakes are high: three, possibly even four Hackernews have declared themselves optimistic, while the rest have moved on to arguing about whether adtech or cancer research gets more funding, a debate that will be settled by the same market forces that brought us the Courage Notification.